DK1109570T3 - Modulation af hukommelseseffektor-T-celler med et CD2-bindemiddel - Google Patents

Modulation af hukommelseseffektor-T-celler med et CD2-bindemiddel

Info

Publication number
DK1109570T3
DK1109570T3 DK99968216T DK99968216T DK1109570T3 DK 1109570 T3 DK1109570 T3 DK 1109570T3 DK 99968216 T DK99968216 T DK 99968216T DK 99968216 T DK99968216 T DK 99968216T DK 1109570 T3 DK1109570 T3 DK 1109570T3
Authority
DK
Denmark
Prior art keywords
cells
binder
modulation
memory effector
effector
Prior art date
Application number
DK99968216T
Other languages
English (en)
Inventor
Daniel Magilavy
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1109570T3 publication Critical patent/DK1109570T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK99968216T 1998-08-31 1999-08-31 Modulation af hukommelseseffektor-T-celler med et CD2-bindemiddel DK1109570T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9845698P 1998-08-31 1998-08-31

Publications (1)

Publication Number Publication Date
DK1109570T3 true DK1109570T3 (da) 2006-03-06

Family

ID=22269362

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99968216T DK1109570T3 (da) 1998-08-31 1999-08-31 Modulation af hukommelseseffektor-T-celler med et CD2-bindemiddel

Country Status (26)

Country Link
US (2) US20020009446A1 (da)
EP (1) EP1109570B1 (da)
JP (1) JP2002523071A (da)
KR (1) KR20010085687A (da)
CN (1) CN100473417C (da)
AT (1) ATE306932T1 (da)
AU (1) AU764020B2 (da)
BR (1) BR9913285A (da)
CA (1) CA2339299C (da)
CZ (1) CZ298238B6 (da)
DE (1) DE69927831T2 (da)
DK (1) DK1109570T3 (da)
EA (1) EA005948B1 (da)
EE (1) EE200100123A (da)
ES (1) ES2252999T3 (da)
HK (1) HK1040186A1 (da)
HU (1) HUP0103563A3 (da)
IL (2) IL141486A0 (da)
IS (1) IS5848A (da)
MX (1) MXPA01002111A (da)
NO (1) NO20010956L (da)
NZ (1) NZ510831A (da)
PL (1) PL346339A1 (da)
TR (1) TR200100607T2 (da)
WO (1) WO2000012113A2 (da)
ZA (1) ZA200101213B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE69927831T2 (de) * 1998-08-31 2006-07-20 Biogen, Inc., Cambridge Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
GEP20063828B (en) * 2001-02-01 2006-05-10 Biogen Inc Methods for Treating or Preventing Skin Disorders Using CD2-Binding Agents
WO2003009740A2 (en) * 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
AU2004279742A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
WO2005077018A2 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
KR20070011558A (ko) * 2004-05-04 2007-01-24 제네상스 파머슈티컬스, 아이엔씨. 일배체형 마커 및 치료에 대한 반응을 측정하기 위해 이를이용하는 방법
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
SI2021025T1 (sl) * 2006-05-12 2017-02-28 Ith Immune Therapy Holdings Ab Postopek in sredstva za zdravljenje vnetne črevesne bolezni
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
WO2010029317A2 (en) 2008-09-10 2010-03-18 Ibd Column Therapies International Ab Treating inflammatory conditions
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
CA3094756A1 (en) * 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
WO2020236797A1 (en) * 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579844A (en) * 1976-05-13 1986-04-01 Johnson & Johnson Topical anti-inflammatory drug therapy
EP0091539B2 (en) * 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
JPH0763830B2 (ja) * 1985-11-26 1995-07-12 アスモ株式会社 ダイカスト鋳造金型への離型剤塗布方法
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
WO1990008187A1 (en) * 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5122514A (en) * 1990-04-23 1992-06-16 Abbott Laboratories Psoriasis treatment
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
WO1992016622A1 (en) * 1991-03-12 1992-10-01 Biogen, Inc. Cd2-binding domain of lymphocyte function associated antigen 3
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
US5511563A (en) * 1991-06-21 1996-04-30 Diamond; Donald A. Apparatus and method for treating rheumatoid and psoriatic arthritis
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
JPH07502495A (ja) * 1991-10-07 1995-03-16 バイオゲン　インコーポレイテッド 特定種のｌｆａ−３またはｃｄ２結合蛋白質を投与することによる同種移植または異種移植の寛容性を改善するための方法
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5817311A (en) * 1993-03-05 1998-10-06 Universite Catholique De Louvain Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
US5951983A (en) * 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US5730979A (en) * 1993-03-05 1998-03-24 Universite Catholique Delouvain LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
RU2166512C2 (ru) * 1995-01-16 2001-05-10 Коммонвелт Сайентифик Энд Индастриал Рисерч Организейшн Конъюгаты терапевтического соединения с жирной кислотой
DE69927831T2 (de) * 1998-08-31 2006-07-20 Biogen, Inc., Cambridge Modulierung von gedächtnis-effector- zellen unter verwendung eines cd2-bindungsagens
US6337337B1 (en) * 1998-09-03 2002-01-08 Carol J. Buck Methods for treating disorders responsive to DHFR-inhibition
GEP20063828B (en) * 2001-02-01 2006-05-10 Biogen Inc Methods for Treating or Preventing Skin Disorders Using CD2-Binding Agents
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders

Also Published As

Publication number Publication date
NO20010956D0 (no) 2001-02-26
US20020009446A1 (en) 2002-01-24
BR9913285A (pt) 2001-05-15
DE69927831D1 (de) 2006-03-02
ZA200101213B (en) 2002-02-13
HK1040186A1 (zh) 2002-05-31
CA2339299A1 (en) 2000-03-09
DE69927831T2 (de) 2006-07-20
EP1109570B1 (en) 2005-10-19
JP2002523071A (ja) 2002-07-30
IL141486A0 (en) 2002-03-10
EE200100123A (et) 2002-06-17
MXPA01002111A (es) 2003-03-27
WO2000012113A2 (en) 2000-03-09
CZ2001725A3 (cs) 2001-08-15
HK1038186A1 (en) 2002-03-08
PL346339A1 (en) 2002-02-11
NZ510831A (en) 2002-12-20
AU6024499A (en) 2000-03-21
EP1109570A2 (en) 2001-06-27
IL141486A (en) 2007-12-03
CZ298238B6 (cs) 2007-08-01
HUP0103563A3 (en) 2004-04-28
ES2252999T3 (es) 2006-05-16
NO20010956L (no) 2001-04-30
WO2000012113A3 (en) 2000-06-29
CN1315866A (zh) 2001-10-03
EA005948B1 (ru) 2005-08-25
CN100473417C (zh) 2009-04-01
TR200100607T2 (tr) 2001-06-21
EA200100304A1 (ru) 2001-10-22
HUP0103563A2 (hu) 2002-01-28
CA2339299C (en) 2009-02-10
KR20010085687A (ko) 2001-09-07
US20060233796A1 (en) 2006-10-19
ATE306932T1 (de) 2005-11-15
AU764020B2 (en) 2003-08-07
IS5848A (is) 2001-02-16

Similar Documents

Publication Publication Date Title
DE69927831D1 (de) Modulierung von gedächtnis-effector t-zellen unter verwendung eines cd2-bindungsagentes
DE69421476D1 (de) Elektrochemisches Immunosensorsystem
EA200100103A1 (ru) Ингибиторы адгезии клеток
DE69722928D1 (de) Verfahren und einrichtung zur verwendung, reinigung und erhaltung von elektrischen wärmequellen und anzünder für rauchsystemen und andere geräte
MX9705005A (es) Inhibidores de la proteina de transferencia de trigliceridos microsomicos y metodo.
DE69500323D1 (de) Antikorrosiver, kathodischer Elektrotauchlack
NO20004053L (no) Glukokortikoid-selektive antiinflammatoriske midler
DK1053240T3 (da) Glucocorticoid-selektiv antiinflammatoriske midler
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
EA200100732A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
DE3887909D1 (de) Brikett für einen elektrischen oder mit Gas betriebenen Rost.
DE3865343D1 (de) Korrosionsinhibitoren.
EP0773993A4 (en) PORCINE CELLS TREATED BY GENETIC ENGINEERING
ATE162794T1 (de) Schrittweise entfernung von monosacchariden vom reduzierenden ende von oligosacchariden und verwendungen davon
FI943850L (fi) 3-alkyylioksi-, aryylioksi- tai aryylialkyylioksibentso(b)tiofeeni-2-karboksamidit soluadheesion inhibiittoreina
DE69412999D1 (de) Raumheizer für feste brennstoffe
DK0839782T3 (da) Fremgangsmåde til hæmning af koksdannelse i pyrolyseovne
DK0651915T3 (da) Sammensætninger og fremgangsmåder til forbedring af den kumulative kapacitet i faste sekundære elektrokemiske celler
FI945328L (fi) Laitos sähköenergian tuottamiseksi polttoaineista, erityisesti biogeenisistä polttoaineista
DE3672701D1 (de) Verfahren zur verwertung von huettenschlacke sowie anlage zur durchfuehrung des verfahrens.
FI940169A0 (fi) Menetelmä hiilen polttamiseksi
DE59202549D1 (de) Verwertungsverfahren für müll-, klärschlamm- und sondermüllverbrennungsasche.
IT8048496A0 (it) Perfici di acciaio senza la emissio procedimento di metallizzazione in ne di fanghi di scarico particolare galvanizzazione di su
NO881289D0 (no) Korrosjonsinhibitor.
PT1017377E (pt) Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina